Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Background: Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development of acquired resistance. The objective of thi...

Full description

Bibliographic Details
Main Authors: Hodgson-Garms, M. (Author), Ioannidis, P. (Author), Jenkins, L.J (Author), Lau, D.K (Author), Lavis, A. (Author), Luk, I.Y (Author), Mariadason, J.M (Author), Vukelic, N. (Author), Weickhardt, A.J (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Acquired resistance
Bladder cancer
bladder tumor
Cell Line, Tumor
EGFR
epidermal growth factor receptor 3
ERBB2
ERBB3
ERBB3 protein, human
female
Female
FGFR3
FGFR3 protein, human
fibroblast growth factor receptor 3
futibatinib
genetics
human
Humans
male
Male
metabolism
microtubule associated protein
Microtubule-Associated Proteins
protein kinase inhibitor
Protein Kinase Inhibitors
pyrazole derivative
Pyrazoles
pyrimidine derivative
Pyrimidines
pyrrole derivative
Pyrroles
Receptor, ErbB-3
Receptor, Fibroblast Growth Factor, Type 3
TACC3 protein, human
Targeted therapy
tumor cell line
Urinary Bladder Neoplasms
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items